Jiecheng Zhang
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 16, 2024
Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure.
Journal: Frontiers in oncology
Published: January 25, 2024
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.
Journal: Nature medicine
Published: December 20, 2023
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: February 23, 2023
Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia.
Journal: Journal of hematology & oncology
Published: January 19, 2023
Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 21, 2022
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 29, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026